Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Macular Edema Clinical Trials

A listing of Macular Edema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (96) clinical trials

Combination OZURDEX & LUCENTIS vs. OZURDEX Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Hypothesis Pseudophakic center-involved DME eyes with incomplete response to 3-6 anti-VEGF injections (i.e., RBZ, BCZ or IAI) will have similar visual acuity gains, as assessed with AUC analysis (change from baseline randomization (Time 0) BCVA letters through 24 weeks 1 week), with a combination treatment regimen consisting of RBZ (0.5 ...

Phase

Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

This study will consist of 2 parts: Part 1 is an open-label, sequential dose escalation part to determine the Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) of TLC399 (ProDex) in patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Part ...

Phase

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .

Phase

Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME

Diabetes mellitus (DM) is the most common endocrine disease in developed countries, with prevalence estimates ranging between 2 to 5% of the world's population. Diabetic retinopathy (DR) and diabetic macular edema (DME) are common microvascular complications in patients with diabetes and may have a sudden and debilitating impact on visual ...

Phase

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively. The main objectives of this observational cohort field study are to evaluate effectiveness of intravitreal aflibercept and to describe follow-up as ...

Phase N/A

A Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)

Phase

Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema

Diabetic macular edema (DME) is the leading cause of blindness among people of working age. Treatment of DME included blood pressure and glycemic control, grid laser, intravitreal injection of steroids (acetonide of triamcinolone, dexamethasone implant, fluocinolone implant) or anti-Vascular endothelial growth factor (VEGF) therapy (Bevacizumab, Ranibizumab, Aflibercept) (2015). The advent ...

Phase N/A

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Efficacy of aflibercept for diabetic macular edema was demonstrated in the phase III, VIVID and VISTA studies. In these studies, aflibercept was injected using the fixed dosing regimen that an intravitreal injection was performed 5 times every 4 weeks and then every 8 weeks. Although the efficacy was comparable to ...

Phase

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO

Central retinal vein occlusion (CRVO) occurs when the main blood vessel that transports blood away from the retina (the very back portion of the eye) becomes blocked, causing the leakage of fluid into the retina and thereby causing a swelling of the macula (the portion of the retina responsible for ...

Phase

Trial of Switching Between Intravitreal Bevacizumab (Avastin )& Intravitreal Dexamethasone (Ozurdex ) for Persistent Diabetic Macular Oedema

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin) and Intravitreal Dexamethasone (Ozurdex) for Persistent Diabetic Macular Oedema (SwitchDMO)

Phase